Patent Number: 
Section: claims

1. A radiolabelling kit comprising:a first vial, wherein said first vial is empty and under vacuum;a second vial, wherein said second vial comprises a suitable amount of acetate buffer for balancing the pH of an eluate from a gallium-68 generator to a pH value ranging from 3 to 5 when said eluate is eluted into the kit; anda third vial, wherein said third vial comprises a lyophilized chelate-functionalized targeting agent and a lyophilized metal inhibitor,wherein the chelator group of said chelate-functionalized targeting agent is selected from the group consisting of: NOTA, NODAGA, Tris(hydroxypyridinone) (THP), HBED, DFO 6SS, B6SS, PLED, YM103, and H2dedpa; andwherein said metal inhibitor is selected from the group consisting of: DOTA, tetra-tBu-DTPA, beta-cyclodextrin and a monosacccharide. 2. The radiolabelling kit according to claim 1, wherein the chelate-functionalized targeting agent is chelate-functionalized prostate-specific membrane antigen (PSMA)-targeting peptide. 3. The radiolabelling kit according to claim 1, wherein the monosaccharide is selected from the group consisting of glucose, fructose, and D-mannose. 4. The radiolabelling kit according to claim 1, wherein the kit comprises one or more of the list consisting of:a needleless transfer device for connecting two vials;an extension line comprising a proximal end adapted for connecting the extension line to a vial adapter and a distal end adapted for connecting the extension line to a needleless syringe;a vial adapter adapted for connecting an extension line or a needleless syringe to a vial; anda needleless syringe. 5. The radiolabelling kit according to claim 1, wherein the chelate-functionalized targeting agent is PSMA-11. 6. The radiolabelling kit according to claim 5, wherein the metal inhibitor is D-mannose. 7. An assembly comprising the radiolabeling kit according to claim 1 and a self-shielded device configured to hold said first vial. 8. The assembly according to claim 7, further comprising a gallium-68 generator. 9. The assembly according to claim 7, wherein the self-shielded device is invertible. 10. The assembly according to claim 7, wherein the self-shielded device comprises a support (2) and a container unit wherein said container unit comprises a container lid (3) and a container vessel (4) comprising a void space dimensioned to hold said first vial; and wherein the support comprises a base (1) and extending from the base and in fixed relation to the base at least one longitudinal member (6). 11. The assembly according to claim 10, wherein the dimensions of the void space suitable for holding the first vial are at most 10% larger than the dimensions of the first vial. 12. The assembly according to claim 10, wherein the at least one longitudinal member (6) is provided in revolute attachment with respect to the container vessel (4), where an axis of rotation is horizontal, non-parallel to a central axis of the first vial and/or parallel to an underside of the base (1). 13. The assembly according to claim 10, wherein the container lid (3) is in revolute attachment with respect to the container vessel (4), where an axis of rotation is vertical, parallel to a central axis of the first vial and/or non-parallel to an underside of the base (1). 14. The assembly according to claim 10, wherein the container unit is provided with a channel configured to hold a dismountable conduit for connecting the first vial within the self-shielding device to an environment external of the self-shielded device, wherein the channel configured to hold a dismountable conduit is provided at the interface of the container lid (3) and the container vessel (4). 15. The assembly according to claim 7, wherein the chelate-functionalized targeting agent is PSMA-11. 16. The assembly according to claim 15, wherein the metal inhibitor is D-mannose.